miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

Abstract

Aim: Given the encouraging results of the p53-Mdm2 inhibitor RG7388 in clinical trials and the vital function of miR-16-5p in suppressing cell proliferation, the aim of the present study was to investigate the combined impact of RG7388 and miR-16-5p overexpression on the childhood acute lymphoblastic leukemia (chALL).

Methods: miRTarBase and miRDB, along with KEGG and STRING databases, were used to predict miR-16-5p target genes and explore protein-protein interaction networks, respectively. B- and T-lymphoblastic cell lines, in addition to patient primary cells, were treated with RG7388. Ectopic overexpression of miR-16-5p in Nalm6 cell line was induced through cell electroporation and transfection of microRNA mimics was confirmed by qRT-PCR. Cell viability was evaluated using the MTT assay. Western blot analyses were performed to evaluate the effects of RG7388 and miR-16-5p upregulation on the protein levels of p53 and its downstream target genes in chALL cells. Paired sample t-test was employed for statistical analyses.

Results: MTT assay showed RG7388-induced cytotoxicity in wild-type p53 Nalm6 cell line and p53 functional patient primary cells. However, CCRF-CEM and p53 non-functional leukemic cells indicated drug resistance. Western blot analyses validated the bioinformatics results, confirming the downregulation of WIP1, p53 stabilization, as well as overexpression of p21^WAF1 and Mdm2 proteins in Nalm6 cells transfected with miR-16-5p. Moreover, enhanced sensitivity to RG7388 was observed in the transfected cells.

Conclusion: This is the first study indicating the mechanistic importance of miR-16-5p overexpression in chALL and its inhibitory role in leukemia treatment when combined with the p53-Mdm2 antagonist, RG7388. These findings might be useful for researchers and clinicians to pave the way for better management of chALL.

Keywords

Pediatric ALL / miR-16-5p / RG7388 / PPM1D / p53

References

[1] Terwilliger T.Acute lymphoblastic leukemia: a comprehensive review and 2017 update.Blood Cancer J2017;7:e577 PMCID:PMC5520400

[2] Ghodousi ES,Rahgozar S.Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL.Jpn J Clin Oncol2020;50:671-8

[3] Khoo KH,Lane DP.Drugging the p53 pathway: understanding the route to clinical efficacy.Nat Rev Drug Discov2014;13:217-36

[4] Kojima K,Andreeff M.Pharmacological activation of wild-type p53 in the therapy of leukemia.Exp Hematol2016;44:791-8 PMCID:PMC5062953

[5] Erba HP,Shami PJ.Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.Blood Adv2019;3:1939-49 PMCID:PMC6616264

[6] Zhu H,Ji Y et al.Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.J Hematol Oncol2022;15:1-23 PMCID:PMC9277894

[7] Wang S.Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.European Journal of Medicinal Chemistry2022:114334

[8] Tisato V,Gonelli A,Zauli G.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.J Hematol Oncol2017;10:1-17 PMCID:PMC5496368

[9] O'Brien J,Zayed Y.Overview of microRNA biogenesis, mechanisms of actions, and circulation.Front Endocrinol (Lausanne)2018;9:402 PMCID:PMC6085463

[10] Deng W,Dorrah K.The role of PPM1D in cancer and advances in studies of its inhibitors.Biomed Pharmacother2020;125:109956 PMCID:PMC7080581

[11] Esfandiari A,Nakjang S.Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.Mol Cancer Ther2016;15:379-91 PMCID:PMC4785723

[12] Issler MVC.MicroRNA-16 feedback loop with p53 and Wip1 can regulate cell fate determination between apoptosis and senescence in DNA damage response.PLoS One2017;12:e0185794 PMCID:PMC5624635

[13] Zhang X,Mlotshwa S et al.Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.Cancer research2010;70:7176-86 PMCID:PMC2940956

[14] Dogan S,Cilic A.Structural analysis of microRNAs in myeloid cancer reveals consensus motifs.Genes2022;13:1152 PMCID:PMC9316571

[15] Yeh CH,Nicot C.Clinical significance of microRNAs in chronic and acute human leukemia.Mol Cancer2016;15:37 PMCID:PMC4867976

[16] Acunzo M.Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia.Clin Chem2016;62:655-6 PMCID:PMC4963818

[17] Hsu SD,Wu WY.miRTarBase: a database curates experimentally validated microRNA-target interactions.Nucleic Acids Res2011;39:D163-9 PMCID:PMC3013699

[18] Wong N.miRDB: an online resource for microRNA target prediction and functional annotations.Nucleic Acids Res2015;43:D146-52 PMCID:PMC4383922

[19] Kanehisa M,Kawashima M,Tanabe M.KEGG as a reference resource for gene and protein annotation.Nucleic Acids Res2016;44:D457-62 PMCID:PMC4702792

[20] Szklarczyk D,Nastou KC.The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets.Nucleic Acids Res2021;49:D605-12 PMCID:PMC7779004

[21] Pozzo F,Peragine N.Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.J Hematol Oncol2013;6:83 PMCID:PMC4222122

[22] Franklin M,Matheson E.Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.Cancer Med2018;7:4744-54 PMCID:PMC6144150

[23] Miller AJ,Norstrom EM.Protein electrophoretic migration data from custom and commercial gradient gels.Data Brief2016;9:1-3 PMCID:PMC5007585

[24] Leeuwen FN. Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.Haematologica2020;105:10-1 PMCID:PMC6939537

[25] Huang FL,Li CL,Yu SJ.Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments.Oncol Lett2020;20:448-54 PMCID:PMC7285861

[26] Zanjirband M,Lunec J.Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.Oncotarget2016;7 PMCID:PMC5129997

[27] Zanjirband M,Edmondson RJ.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Oncotarget2017;8 PMCID:PMC5642516

[28] Ciardullo C,Woodhouse L.Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.Haematologica2019;104:2429-42 PMCID:PMC6959162

[29] Seipel , Miguel A. T. Marques , Corinne Sidler , Pabst BUMaT. The cellular p53 inhibitor MDM2 and the growth factor receptor FLT3 as biomarkers for treatment responses to the MDM2-inhibitor idasanutlin and the MEK1 inhibitor cobimetinib in acute myeloid leukemia.Cancers2018;10 PMCID:PMC6025168

[30] Berberich A,Thomé CM.Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.Clin Cancer Res2019;25:253-65

[31] Wu CE,Esfandiari A,Lovat P.ATM dependent DUSP6 modulation of p53 involved in synergistic targeting of MAPK and p53 pathways with trametinib and MDM2 inhibitors in cutaneous melanoma.Cancers (Basel)2018;11:3 PMCID:PMC6356368

[32] Zhao Y,Bernard D.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.J Med Chem2015;58:1038-52 PMCID:PMC4329994

[33] Holzer P,Furet P.Discovery of a Dihydroisoquinolinone derivative (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors.J Med Chem2015;58:6348-58

[34] Ferretti S,Berger M.Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials.Cancer Research2016;76:1224-1224

[35] Zanjirband M.Targeting p53-MDM2 interaction using small molecule inhibitors and the challenges needed to be addressed.Curr Drug Targets2019;20:1091-111

[36] Trino S,Erriquez D.Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.Oncotarget2016;7:12951-61 PMCID:PMC4914334

[37] Gu L,Findley HW.MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.Leukemia2008;22:730-9 PMCID:PMC3477706

[38] Chiaretti S,Tavolaro S.TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.Haematologica2013;98:e59-61 PMCID:PMC3640132

[39] Reis B,Chen G.Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.Haematologica2016;101:e185-8 PMCID:PMC5004378

[40] Andreeff M,Yee K.Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in Leukemia.Clin Cancer Res2016;22:868-76 PMCID:PMC4809642

[41] Kaddar T,Bertrand Y.Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation.Leuk Res2009;33:1217-23

[42] Tate JG,Jubb HC.COSMIC: the catalogue of somatic mutations in cancer.Nucleic Acids Res2019;47:D941-7 PMCID:PMC6323903

[43] Inoue K.Haploinsufficient tumor suppressor genes.Adv Med Biol2017;118:83-122 PMCID:PMC5494974

[44] Sriraman A,Wienken M,Li Y.Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.Oncotarget2016;7:31623 PMCID:PMC5077964

[45] Fontana MC,Marconi G.Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a.Cancer Research2019;79:2964-2964

[46] Pechackova S,Benada J,Jenikova G.Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.Oncotarget2016;7:14458 PMCID:PMC4924728

[47] Ma Q,Li Z.microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway.Oncol Rep2013;29:1652-8

[48] Liu Q,Sun F.miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes.Nucleic Acids Res2008;36:5391-404 PMCID:PMC2532718

[49] Cai CK,Tian LY.miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.Oncol Rep2012;28:1764-70

[50] Pekarsky Y,Croce CM.BCL2 and miR-15/16: from gene discovery to treatment.Cell Death Differ2018;25:21-6 PMCID:PMC5729525

[51] Cimmino A,Fabbri M.miR-15 and miR-16 induce apoptosis by targeting BCL2.Proc Natl Acad Sci U S A2005;102:13944-9 PMCID:PMC1236577

[52] Xia L,Du R.miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.Int J Cancer2008;123:372-9

[53] Forterre A,Aminova S.A comprehensive review of cancer microRNA therapeutic delivery strategies.Cancers (Basel)2020;12:1852 PMCID:PMC7408939